Drosophila melanogaster as a rapid in vivo assay system for preclinical anti‐seizure medication testing [PDF]
Epilepsia OpenEpilepsy represents a significant medical challenge, with a third of patients failing to achieve seizure freedom despite the use of multiple different anti‐seizure medications (ASM). Drug resistance is common in genetically caused epilepsies.
Emma V. Töfflinger +4 more
doaj +2 more sources
Stiripentol for the treatment of refractory status epilepticus
Neurological Research and PracticeBackground Status epilepticus (SE) is one of the most common neurological emergencies and an acutely life-threatening condition characterized by high mortality and morbidity.
Leona Möller +9 more
doaj +2 more sources
Real-world disproportionality analysis of sleep disturbances associated with antiseizure medications in epilepsy: a pharmacovigilance study [PDF]
Frontiers in PharmacologyObjectiveReal-world evidence characterizing the safety profiles of antiseizure medications (ASMs) concerning sleep disturbances remains limited. This study aimed to systematically evaluate the reporting patterns and safety signals of ASMs-related sleep ...
Chen Gou +7 more
doaj +2 more sources
Perampanel Reduces Hyperthermia-Induced Seizures in Dravet Syndrome Mouse Model
Frontiers in Pharmacology, 2021 Treatment options for Dravet syndrome are limited. The aim of this study was to evaluate the antiepileptic effect of the AMPA receptor antagonist perampanel (PER) on a mouse model of Dravet syndrome (Scn1aE1099X/+).
Shih-Yin Ho +8 more
doaj +1 more source
Frontiers in Pharmacology, 2022 Purpose: Recently, the U.S. Food and Drug Administration (FDA) approved stiripentol, cannabidiol, and fenfluramine to treat patients with Dravet syndrome (DS). Moreover, soticlestat was determined as a promising new drug for the treatment of DS as it has
Jianhua Wu +6 more
doaj +1 more source
Therapeutic Advances in Neurological Disorders, 2023 Developmental and epileptic encephalopathies (DEEs) are rare neurodevelopmental disorders characterised by early-onset and often intractable seizures and developmental delay/regression, and include Dravet syndrome and Lennox–Gastaut syndrome (LGS ...
Graeme J. Sills
doaj +1 more source
, 1992 The anticonvulsant potency and pharmacokinetics of the enantiomers of stiripentol were compared using the intravenous pentyl-enetetrazol infusion seizure model in the rat.
R. H. +10 more
core +5 more sources
Efficacy and Safety of Long-Term Treatment with Stiripentol in Children and Adults with Drug-Resistant Epilepsies: A Retrospective Cohort Study of 196 Patients [PDF]
, 2022 BACKGROUND: Stiripentol is an antiseizure medication with multiple potential mechanisms of action, indicated as adjunctive therapy in people with Dravet syndrome, whose seizures are not adequately controlled with clobazam and valproate.
De Masi, Salvatore +5 more
core +2 more sources
Lactate Dehydrogenase Inhibitors Suppress Borrelia burgdorferi Growth In Vitro
Pathogens, 2023 Borrelia burgdorferi, the causative agent of Lyme disease, has a highly reduced genome and relies heavily on glycolysis for carbon metabolism. As such, established inhibitors of lactate dehydrogenase (LDH) were evaluated in cultures to determine the ...
Adam Lynch +4 more
doaj +1 more source
Stiripentol efficacy and safety in Dravet syndrome: a 12-year observational study [PDF]
, 2018 AIM: To assess long‐term safety and efficacy of stiripentol as an antiepileptic medication for people with Dravet syndrome. METHOD: A prospective, observational open‐label study (2003–2015) of the efficacy and long‐term safety of stiripentol in ...
Patil, SG +9 more
core +2 more sources